The current stock price of BSTG is 0.23 null. In the past month the price decreased by -25.32%. In the past year, price decreased by -75.53%.
ChartMill assigns a fundamental rating of 1 / 10 to BSTG. BSTG may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months BSTG reported a non-GAAP Earnings per Share(EPS) of -0.614. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -25627.78% | ||
| ROA | -297.23% | ||
| ROE | -1081.17% | ||
| Debt/Equity | 0 |
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.
Biostage Inc.
84 October Hill Road Suite 11
Holliston MA 01746
CEO: James McGorry
Phone: 774-233-7300
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.
The current stock price of BSTG is 0.23 null. The price decreased by -23.33% in the last trading session.
BSTG does not pay a dividend.
BSTG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
BSTG stock is listed on the Nasdaq exchange.
Biostage Inc. (BSTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BSTG.